Clinical Response to Ingenol Mebutate in Patients With Actinic Keratoses
| Autor: | Á. Flórez, C. de la Torre, Laura Salgado-Boquete, Gonzalo Peón, María Teresa Abalde, A. Batalla, Carlos Feal |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Histology business.industry medicine.medical_treatment Actinic keratosis Ingenol mebutate Cryotherapy Imiquimod macromolecular substances Dermatology Actinic keratoses medicine.disease Pathology and Forensic Medicine chemistry.chemical_compound Diclofenac chemistry medicine Field cancerization business Local Reaction medicine.drug |
| Zdroj: | Actas Dermo-Sifiliográficas (English Edition). 106:e55-e61 |
| ISSN: | 1578-2190 |
| DOI: | 10.1016/j.adengl.2015.10.012 |
| Popis: | Cryotherapy is the most common treatment for actinic keratosis, but its effect is limited to individual lesions. Several topical drugs, however, are available that, in addition to treating individual actinic keratoses, target field cancerization and thereby act on subclinical lesions. Examples are 5-fluorouracil, imiquimod, diclofenac, and ingenol mebutate. We report on 17 patients with actinic keratoses treated with ingenol mebutate and describe our findings on treatment effectiveness, adherence, and tolerance. Complete and partial response rates were 35% and 53%, respectively. Ninety-four percent of patients fully adhered to treatment and 18% developed severe local reactions. Ingenol mebutate is an effective treatment for actinic keratosis. Although it has a similar rate of local reactions to other treatments available for actinic keratosis, its short treatment regimen favors better adherence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect